Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain-Reference-Cited by-同舟云学术

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

Published:2021-01 Issue: Volume:Volume 17 Page:125-137
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Kearns Benjamin^ORCID,Cooper Katy^ORCID,Cantrell Anna,Thomas Chloe

Publisher

Informa UK Limited

Reference92 articles.

1. A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective

2. Global healthcare expenditure on diabetes for 2010 and 2030

3. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study

4. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls

5. Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence;ClinicoEconomics and Outcomes Research;2024-09

2. ANTIPSYCHOTIC DRUGS: THREE GENERATIONS OF ANTIPSYCHOTICS;ARMENIAN JOURNAL OF MENTAL HEALTH;2024

3. New trends in schizophrenia treatment;Psychiatrie pro praxi;2023-10-16

4. Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety;Neuropsychiatric Disease and Treatment;2023-10

5. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-09